DSpace Community:https://repositorio.ufu.br/handle/123456789/51622026-09-02T06:53:15Z2026-09-02T06:53:15ZImpacto dos subtipos moleculares e variáveis clínico-patológicas nos desfechos do câncer de mama: um estudo entre grandes bases de dadoshttps://repositorio.ufu.br/handle/123456789/497962026-08-25T06:22:47Z2026-11-03T00:00:00ZTitle: Impacto dos subtipos moleculares e variáveis clínico-patológicas nos desfechos do câncer de mama: um estudo entre grandes bases de dados
Abstract: Breast cancer represents a major global health challenge, and the use of publicly available databases can contribute to a more comprehensive understanding of disease patterns. Given the potential of these data sources to support complementary analyses, this study aimed to explore different publicly available databases to investigate demographic, tumor, and therapeutic characteristics of breast cancer. An observational, retrospective study was conducted using hospital-based, population-based, and molecular records from four databases: the São Paulo Hospital-Based Cancer Registry (HBCR), the National HBCR, the Surveillance, Epidemiology, and End Results (SEER) Program, and the genomic and clinical data from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC). Together, these four databases comprised 1,128,269 breast cancer records. Diagnoses were made between 2000 and 2015, except for the METABRIC database. Fine-Gray competing risks modeling was employed to evaluate tumor recurrence over a 120-month follow-up period, stratified into two time intervals (0–60 and 61–120 months). Cox proportional hazards models were applied to estimate 5-year overall and cause-specific survival. Road travel distances to cancer treatment facilities in Brazil were estimated using the geobr and osrm statistical packages. All analyses were performed in the RStudio computing environment, version 2026.01.1+403. Independent predictors of the average risk of tumor recurrence included tumor size, the number of positive lymph nodes, histological grade 3, and intrinsic molecular subtypes defined by the PAM50 gene expression signature. Temporal dynamics analysis demonstrated that the risk of tumor recurrence was not constant over time. Regarding 5-year survival, age and tumor stage were independent predictors of the average risk of overall and cause-specific mortality. Year of diagnosis was inversely associated with the risk of cause-specific mortality, serving as a temporal marker of changes occurring throughout the study period. An average reduction of 2.81% in the Sâo Paulo HBCR and 2.96% in the population-based registry was observed in the risk of cause-specific mortality for each more recent year of diagnosis. In the National HBCR, 52.09% of the sample received treatment outside their municipality of residence. Median road travel distances by treatment modality ranged from 76.6 km for hormone therapy to 114.0 km for immunotherapy. Geographic mapping revealed inequalities in the distribution of oncology services, demonstrating that treatment centers were highly concentrated in the Southeast, South, and Northeast regions of Brazil. The study concludes that different databases provide complementary information that expands the analytical capabilities for investigating breast cancer outcomes, enabling analyses that would not be possible using a single data source. These findings highlight the value of combining information from multiple data sources to support researchers and healthcare decision-makers in monitoring disease patterns and planning oncology care strategies.2026-11-03T00:00:00ZPerfil clínico, laboratorial e transfusional de pacientes oncológicos ambulatoriais: análise de três anos em hospital público brasileirohttps://repositorio.ufu.br/handle/123456789/494742026-08-13T06:29:05Z2026-04-24T00:00:00ZTitle: Perfil clínico, laboratorial e transfusional de pacientes oncológicos ambulatoriais: análise de três anos em hospital público brasileiro
Abstract: Cancer represents a major public health concern and is frequently associated with
hematological alterations resulting from both the disease itself and the therapies employed. In
this context, transfusion support and the evaluation of laboratory parameters play a central role
in the clinical management of these patients. This study aimed to characterize the clinical,
laboratory, and transfusional profile of outpatient cancer patients treated at a public hospital in
Brazil. This was a retrospective observational study including 389 patients treated between
January 2020 and December 2022. The population had a median age of 62 years, with a slight
predominance of females (53%). Solid tumors accounted for 52.9% of cases, followed by
lymphoid (31.4%) and myeloid neoplasms (15.4%). During the study period, a total of 677
units of blood components were transfused, predominantly red blood cells concentrates
(81.4%), with a median of two units per patient. Anemia was the main indication for transfusion
(74.1%). Laboratory evaluation revealed consistent hematological abnormalities, including
increased red cell distribution width (RDW), suggesting significant erythrocyte morphological
heterogeneity. Additionally, elevated neutrophil-to-lymphocyte ratio (NLR) and platelet-to-
lymphocyte ratio (PLR) indicated the presence of systemic inflammation. In the transfusional
analysis, patients with solid tumors showed a higher intensity of red blood cell transfusion,
whereas those with hematological neoplasms exhibited a higher frequency of platelet
transfusion. Notably, platelet transfusion intensity was higher in patients with solid tumors,
while among hematological neoplasms, the lymphoid subgroup demonstrated a greater relative
demand for this component. Irregular antibody positivity was identified in 4.1% of patients,
with a predominance of alloantibodies from the Rh and Kell systems. The occurrence of
transfusion reactions was low, with three events reported. In conclusion, outpatient cancer
patients present a high transfusional demand, with distinct patterns according to the type of
neoplasm, as well as laboratory findings consistent with systemic inflammation and
erythropoietic dysregulation. These findings highlight the importance of individualized
transfusion strategies and contribute to improving clinical care in this population.2026-04-24T00:00:00ZDesenvolvimento de estratégias antivirais frente a vírus emergenteshttps://repositorio.ufu.br/handle/123456789/494402026-08-12T06:28:48Z2026-07-31T00:00:00ZTitle: Desenvolvimento de estratégias antivirais frente a vírus emergentes
Abstract: Emerging viruses pose growing threats to public health, particularly in Brazil, where environmental
and sociodemographic factors favour epidemic outbreaks. This work aimed to identify and
characterise antiviral compounds against the emerging viruses Orthobunyavirus oropoucheense
(OROV) and Betacoronavirus pandemicum (SARS-CoV-2) through medium-throughput screening
of the Pandemic Response Box (PRB) and Global Health Priority Box (GHPB) libraries from the
Medicines for Malaria Venture (MMV). OROV is the causative agent of Oropouche fever, which
caused over 13,000 cases in Brazil in 2024, with unprecedented geographical expansion, vertical
transmission, neurological complications and confirmed fatalities, with no approved antiviral
treatment available. SARS-CoV-2, responsible for the COVID-19 pandemic with over 779 million
cases recorded through 2026, remains a therapeutic challenge, particularly against the Delta and
Omicron variants of concern. The experimental approach employed fluorescent reporter viruses,
BUNV-eGFP (Bunyamwera virus with an enhanced green fluorescent protein reporter) as a
prototypic model for OROV, and SARS-CoV-2-mCherry (SARS-CoV-2 with a monomeric red
fluorescent protein reporter) for direct screening, in A549 and A549-AT cells, with automated
readout using the IncuCyte S3 system. Of the 640 compounds tested, active hits were identified and
validated for both viral targets. Against OROV, nine compounds from the PRB inhibited BUNV
replication by more than 90%. Following validation against wild-type OROV (epidemic strain
AM0088), three hits were confirmed: Trimetrexate, MMV1634385, and GSK-983, being GSK the
compound with greatest inhibition (EC50 = 0.5 μM against OROV; DHODH inhibitor; SI > 20),
reported here for the first time as an anti-orthobunyavirus compound and identified as the most
promising candidate. Against SARS-CoV-2, two hits were mechanistically characterised.
Revaprazan (EC50 = 1.3 μM; SI > 7.7), a clinically approved potassium-competitive acid blocker
(P-CAB), inhibited viral entry while retaining activity against Delta and Omicron BA.2,
representing the first report of antiviral activity for a P-CAB-class compound. Milbemectin (EC50
= 1.6 μM; SI > 6), a milbemycin-class macrolide antiparasitic structurally related to ivermectin,
acted predominantly at post-entry stages, interfering with virion assembly and egress. Together,
these findings establish GSK-983, Revaprazan and Milbemectin as priority candidates for
preclinical investigation, expand the antiviral spectrum of compounds with established safety
profiles, and validate the fluorescent reporter-based screening platform as a robust strategy for
antiviral discovery against emerging viral threats.2026-07-31T00:00:00ZAnálise in silico e in vitro da interação da BthTX-I, uma PLA2 Lys-49 da peçonha de Bothrops jararacussu, com proteínas-alvo associadas à infecção por Toxoplasma gondiihttps://repositorio.ufu.br/handle/123456789/494192026-08-12T06:27:35Z2025-12-12T00:00:00ZTitle: Análise in silico e in vitro da interação da BthTX-I, uma PLA2 Lys-49 da peçonha de Bothrops jararacussu, com proteínas-alvo associadas à infecção por Toxoplasma gondii2025-12-12T00:00:00Z